Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
about
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
P2860
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@en
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@nl
type
label
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@en
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@nl
prefLabel
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@en
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@nl
P2093
P2860
P356
P1433
P1476
Selective HDAC inhibition by A ...... litaxel in solid tumor models.
@en
P2093
Ingrid Almeciga-Pinto
John H van Duzer
Matthew Jarpe
Pengyu Huang
Ralph Mazitschek
Simon S Jones
Steven N Quayle
P2860
P304
P356
10.18632/ONCOTARGET.13738
P407
P577
2016-12-01T00:00:00Z